Updates in COPD Management

CE

Strategies for Pharmacists to Overcome Current Challenges and Integrate Novel Maintenance Therapies for the Management of COPD

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: January 29, 2024

Expiration: January 28, 2025

J. Andrew Woods
J. Andrew Woods, PharmD, BCPS

Activity

Progress
1 2
Course Completed

Introduction

In this module, J. Andrew Woods, PharmD, BCPS, provides an overview of novel therapies for chronic obstructive pulmonary disease (COPD) maintenance, recent updates from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidance, and practical strategies to improve patient and disease outcomes.

The key points discussed in this module are illustrated with thumbnails from an accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module.

ProCE plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with COPD do you provide care for in a typical week?

Which of the following is recommended by the GOLD 2024 report for a patient with group A COPD?

A patient with COPD is receiving vilanterol/umeclidinium with good technique and adherence. He has had 4 hospital admissions for exacerbations in the past year and has a blood eosinophil count of 355 cells/μL. What is the next best step for his treatment?

Which of the following devices would you select for an older patient with osteoarthritis of the hands and poor inspiratory effort?

How often do you currently use the teach-back method at every visit?